Abstract
A mass chemotherapy campaign to treat onchocerciasis with ivermectin was carried out in northern Cameroon, in the North Vina valley, a savanna area that is part of the extended Vina-Pendé-Longone focus. More than 20,000 people aged five years and over were treated at least once and more than 30,000 treatments were distributed. One to four treatments were given at intervals of six months or one year. Clinical and parasitological examinations of representative samples of the treated population and full ophthalmological examinations of males aged 15 to 35 years were carried out before each treatment to assess the efficacy of the different protocols of treatment. Secondary effects were recorded daily during the week after administration of ivermectin in the whole population treated. The evolution of arterial blood pressure was monitored over seven days in about 300 adults living in the hyperendemic region. The impact of mass treatment on natural transmission of the disease was evaluated by daily capture and dissection of blackflies during the month before and the two months after treatment. All levels of onchocerciasis endemicity were represented in the study area (maximum community microfilarial load (CMFL), 300 microfilariae per biopsy). Six months and one year after the first treatment, loads were down by more than 90% and more than 60% respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dadzie K. Y., Bird A. C., Awadzi K., Schulz-Key H., Gilles H. M., Aziz M. A. Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis. Br J Ophthalmol. 1987 Feb;71(2):78–85. doi: 10.1136/bjo.71.2.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Larivière M., Beauvais B., Aziz M., Garin J. F., Abeloos J., Derouin F., Bamba M., Bossebceuf C., Ferly-Therizol M., Sarfati C. Etude en Côte-d'Ivoire (1985-1987) de l'efficacité et de la tolérance de l'ivermectine (Mectizan) dans l'onchocercose humaine. I. Etude comparative en double insu de 220 sujets onchocerquiens traités par dose unique orale de 100, 150 ou 200 mcg/kg. Bull Soc Pathol Exot Filiales. 1989 Jan;82(1):35–47. [PubMed] [Google Scholar]
- Moreau J. P., Prost A., Prod'hon J. Essai de normalisation de la méthodologie des enquêtes clinco-parasitologiques sur l'onchocercose en Afrique de l'Ouest. Med Trop (Mars) 1978 Jan-Feb;38(1):43–51. [PubMed] [Google Scholar]
- Prost A., Prod'hon J. Le diagnostic parasitologique de l'onchocercose. Revue critique des methodes en usage. Med Trop (Mars) 1978 Sep-Oct;38(5):519–532. [PubMed] [Google Scholar]
- Remme J., Ba O., Dadzie K. Y., Karam M. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. Bull World Health Organ. 1986;64(5):667–681. [PMC free article] [PubMed] [Google Scholar]
- Remme J., Dadzie K. Y., Rolland A., Thylefors B. Ocular onchocerciasis and intensity of infection in the community. I. West African savanna. Trop Med Parasitol. 1989 Sep;40(3):340–347. [PubMed] [Google Scholar]
- Taylor H. R., Greene B. M. The status of ivermectin in the treatment of human onchocerciasis. Am J Trop Med Hyg. 1989 Oct;41(4):460–466. doi: 10.4269/ajtmh.1989.41.460. [DOI] [PubMed] [Google Scholar]
- Whitworth J. A., Morgan D., Maude G. H., Taylor D. W. Community-based treatment with ivermectin. Lancet. 1988 Jul 9;2(8602):97–98. doi: 10.1016/s0140-6736(88)90022-0. [DOI] [PubMed] [Google Scholar]